AIM ImmunoTech Inc.
AMEXAIM ImmunoTech arrives at its May 22 earnings event in the wake of one of the most severe drawdowns among micro-cap biotechs this year — down 56% in a single month, with the stock at $0.25. The price collapse is the most striking fact about the setup. The stock lost a quarter of its value in just the past week. That crash followed the prior print on March 27, where AIM shed more…
Snapshot as of 1 Jul 2026
AIM ImmunoTech arrives at its May 22 earnings event in the wake of one of the most severe drawdowns among micro-cap biotechs this year — down 56% in a single month, with the stock at $0.25. The price collapse is the…
AIM ImmunoTech enters its May 18 earnings release having shed more than half its value in a single month — and with every major short-side signal moving in the same direction at once: covering, cheaper borrows, and a…
AIM ImmunoTech arrives at its May 18 earnings event in a deeply compromised technical state — the stock has fallen 56% over the past month to $0.253, and Q1 results released late Friday only deepened the concern, with…
AIM ImmunoTech heads into its May 18 earnings date with short interest surging, borrowing costs punishingly high, and a Phase 3 trial announcement doing little to arrest a brutal month-long slide. Short positioning…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for AIM — free to start on ORTEX.
Sign up for free →Open AIM on ORTEX